Reference Detail

Ref Type

PMID

Authors

Kyriakos P. Papadopoulos, Anthony W. Tolcher, Amita Patnaik, Drew Warren Rasco, Glenda Chambers, Murali Beeram, Ronald Savage, Terence Hall, Brian E. Schwartz, Julia Kazakin, Patricia LoRusso; START Center for Cancer Care, San Antonio, TX; START, San Anto

Title

Phase 1, first-in-human study of ARQ 087, an oral pan-Fibroblast Growth Factor Receptor (FGFR) inhibitor, in patients (pts) with advanced solid tumors.

Journal	Vol	Issue	Date	Pages	Journal Short Title
J Clin Oncol

URL

http://meetinglibrary.asco.org/content/149025-156

Abstract Text

J Clin Oncol 33, 2015 (suppl; abstr 2545)

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Treatment Approach
No data available in table

Gene Name	Source	Synonyms	Protein Domains	Gene Description	Gene Role
No data available in table

Therapy Name	Drugs	Efficacy Evidence	Clinical Trials
No data available in table

Drug Name	Trade Name	Synonyms	Drug Classes	Drug Description
No data available in table

Filter rows:

Showing 0 to 0 of 0 entries

Gene	Variant	Impact	Protein Effect	Variant Description	Associated with drug Resistance
No data available in table

Filter rows:

Showing 1 to 1 of 1 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
SRC amp	lung non-small cell carcinoma	sensitive	Derazantinib	Case Reports/Case Series	Actionable	In a Phase I trial, Derazantinib (ARQ 087) treatment resulted in 25% tumor reduction and stable disease for 36 weeks in a squamous non-small cell lung carcinoma patient harboring SRC amplification (PMID: 28972963; NCT01752920).	28972963 detail...

Showing 1 to 1 of 1 entries

Filter rows:

Reference Detail

Contact

Filtering

Sorting